Waters Corporation WAT
470.90 USD -4.62 (-0.97%)
At closeNov 11, 2026, 5:05 PM EST
470.90 0.00 0.00%
After hours · Nov 11, 5:05 PM ET
470.65 Day range 483.33
282.77 52-week range 483.33
- YTD
- +23.98%
- 1 year
- +21.95%
News
zacks.com Waters Gains FDA Clearance for Flow Cytometry Tests for Blood Cancers WAT gains FDA clearance for two blood cancer diagnostic tests, advancing standardized testing and expanding its clinical diagnostics portfolio.
benzinga.com Waters Says BD OneFlow LST Test And BD OneFlow B-CLPD T1 Test Receives FDA 510(k) Clearance For Identifying B-Cell Non-Hodgkin Lymphoma BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 Tests now FDA 510(k)-cleared in U.S. for identifying B-cell non-Hodgkin lymphoma (NHL)Delivers 96.3% sensitivity and 98.2% specificity1 in identifying…
prnewswire.com Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 Tests now FDA 510(k)-cleared in U.S. for identifying B-cell non-Hodgkin lymphoma (NHL) Delivers 96.3% sensitivity and 98.2% specificity1 in identifying…
zacks.com Waters Expands Proteomics Reach With MOBILion Systems Acquisition WAT expands its proteomics footprint with the MOBILion acquisition, boosting mass spectrometry capabilities, AI-driven research and clinical testing prospects.
seekingalpha.com Madison Mid Cap Fund Q3 2026 Portfolio Activity The Madison Mid Cap Fund (Class I) returned -2.09% in the third quarter, compared to the Russell Midcap Index return of -3.00%. The top five contributors for the quarter were Gartner, Medpace…
benzinga.com Citigroup Maintains Buy on Waters, Raises Price Target to $536 Citigroup analyst Joanne Wuensch maintains Waters (NYSE:WAT) with a Buy and raises the price target from $470 to $536.
benzinga.com JP Morgan Maintains Neutral on Waters, Raises Price Target to $470 JP Morgan analyst Casey Woodring maintains Waters (NYSE:WAT) with a Neutral and raises the price target from $435 to $470.
benzinga.com TD Cowen Maintains Buy on Waters, Raises Price Target to $530 TD Cowen analyst Dan Brennan maintains Waters (NYSE:WAT) with a Buy and raises the price target from $515 to $530.- benzinga.com Barclays Maintains Overweight on Waters, Raises Price Target to $530 Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Overweight and raises the price target from $500 to $530.
benzinga.com RBC Capital Maintains Outperform on Waters, Raises Price Target to $525 RBC Capital analyst Dan Leonard maintains Waters (NYSE:WAT) with a Outperform and raises the price target from $475 to $525.
247wallst.com Jim Cramer Calls Big Tech ‘Millstones' and Names the ‘New Techs' Taking Over Jim Cramer just declared the companies that supply drug labs and research instruments the true heirs to the data center trade, and three stocks are already beating the NASDAQ-100 by a wide margin…
benzinga.com Keybanc Maintains Overweight on Waters, Raises Price Target to $500 Keybanc analyst Paul Knight maintains Waters (NYSE:WAT) with a Overweight and raises the price target from $460 to $500.
marketbeat.com Waters Q3 Earnings Call Highlights Waters NYSE: WAT reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share of $4.10, as the company cited double-digit organic growth, improving performance in acquired…
zacks.com Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised WAT beats Q3 2026 earnings and revenue estimates, fueled by acquisitions and strong organic growth and raises its full-year revenue and earnings outlook.
benzinga.com Waters CEO Says AI Is Already Fueling Lab Demand As Drugmakers Race to Accelerate Discovery Waters Corporation (WAT) shares jump on strong Q3 earnings beat, raised 2026 outlook, and the strategic acquisition of MOBILion Systems.
seekingalpha.com Waters Corporation (WAT) Q3 2026 Earnings Call Transcript Waters Corporation (WAT) Q3 2026 Earnings Call Transcript
zacks.com Waters (WAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Waters (WAT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
benzinga.com Waters Q3 2026 Earnings Call Transcript Waters (NYSE:WAT) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Waters (WAT) Beats Q3 Earnings and Revenue Estimates Waters (WAT) came out with quarterly earnings of $4.1 per share, beating the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $3.4 per share a year ago.
benzinga.com Waters Sees Q4 Adj EPS $4.58-$4.68 vs $4.67 Est; Sees Sales $1.801B-$1.819B vs $1.789B Est Waters (NYSE:WAT) is looking for Q4 Adj EPS of $4.58-$4.68 vs $4.67 analyst estimate. sees sales of $1.801 billion-$1.819 billion vs $1.789 billion analyst estimate.- benzinga.com Waters Q3 Adj. EPS $4.10 Beats $4.00 Estimate, Sales $1.767B Beat $1.754B Estimate Waters (NYSE:WAT) reported quarterly earnings of $4.10 per share which beat the analyst consensus estimate of $4.00 by 2.5 percent. This is a 20.59 percent increase over earnings of $3.40 per share…
benzinga.com Waters Raises FY2026 Adj EPS Guidance from $14.45-$14.65 to $14.60-$14.70 vs $14.58 Est; Raises FY2026 Sales Guidance from $6.415B-$6.476B to $6.479B-$6.497B vs $6.456B Est Waters (NYSE:WAT) raises FY2026 Adj EPS guidance from $14.45-$14.65 to $14.60-$14.70 vs $14.58 analyst estimate. Raises FY2026 sales outlook from $6.415 billion-$6.476 billion to $6.479…
prnewswire.com Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results Company to Provide Starting 2027 Growth Framework on Earnings Conference Call Third Quarter 2026 Highlights Total reported revenue of $1.767 billion exceeded guidance midpoint by $14 million, led by…- benzinga.com Waters Corporation Acquires Ion Mobility Separation Technology Maker MOBILion Systems; Financial Terms Not Disclosed Waters Corporation (NYSE:WAT), a global life sciences and diagnostics leader, today announced that it has acquired MOBILion Systems, Inc., the pioneer of SLIM high-resolution ion mobility separation…
prnewswire.com Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery Adds MOBILion's breakthrough SLIM high-resolution ion mobility technology, which separates molecules by size, shape and charge in milliseconds, complementing Waters' industry leading mass…
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com Here’s How Much You Would Have Made Owning Waters Stock In The Last 20 Years Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.93% on an annualized basis producing an average annual return of 11.87%. Currently, Waters has a market capitalization of…
zacks.com Waters Gears Up to Report Q3 Results: How to Play the Stock? WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.
prnewswire.com Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software Advances Waters' strategy to bring trusted AI, ML, and automation capabilities to the 500,000 Empower™ Software users who run the world's regulated chromatography labs and support the release of over…
zacks.com Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.
seekingalpha.com First Eagle U.S. Value Fund Q3 2026 Portfolio Review U.S. Fund A Shares (without sales charge) posted a return of 4.36% in third-quarter 2026. The US Fund outperformed the S&P 500 Index in the period. Shares of Meta performed well following the strong…- benzinga.com Waters And Labcorp To Expand Access To BD Onclarity HPV Assay Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic,…
prnewswire.com Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026 Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic,…
zacks.com Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.
prnewswire.com Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only…
invezz.com Two stocks poised to benefit from rotation out of AI Investors looking beyond artificial intelligence (AI) should closely watch two healthcare names – Thermo Fisher Scientific (TMO) and Waters (WAT) – according to Josh Brown. In his latest report, the…
benzinga.com Here’s How Much You Would Have Made Owning Waters Stock In The Last 20 Years Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.71% on an annualized basis producing an average annual return of 11.7%. Currently, Waters has a market capitalization of…
benzinga.com TD Cowen Maintains Buy on Waters, Raises Price Target to $515 TD Cowen analyst Dan Brennan maintains Waters (NYSE:WAT) with a Buy and raises the price target from $475 to $515.- benzinga.com Barclays Maintains Overweight on Waters, Raises Price Target to $500 Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Overweight and raises the price target from $460 to $500.
benzinga.com Nvidia, Micron and Other 5 S&P 500 Stocks With +100% Revenue Growth Micron, Sandisk and Nvidia lead seven S&P 500 stocks that more than doubled quarterly revenue. Six sell AI hardware.
benzinga.com The S&P 500 Is Partying at Record Highs: Only 3% of Its Stocks Were Invited The S&P 500 hit a record high Tuesday, but only 15 of its 504 stocks did too. The median member trades 25% below its own peak.- benzinga.com Guggenheim Maintains Buy on Waters, Raises Price Target to $490 Guggenheim analyst Subbu Nambi maintains Waters (NYSE:WAT) with a Buy and raises the price target from $440 to $490.
- benzinga.com If You Invested $1000 In Waters Stock 20 Years Ago, You Would Have This Much Today Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.95% on an annualized basis producing an average annual return of 11.99%. Currently, Waters has a market capitalization of…
benzinga.com Microsoft To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Monday Analysts raised targets for INSP, SECZ, CLF and WAT, while cutting targets for CRDO, CL and TTMI; ratings remained unchanged.- benzinga.com Goldman Sachs Maintains Buy on Waters, Raises Price Target to $515 Goldman Sachs analyst Evie Koslosky maintains Waters (NYSE:WAT) with a Buy and raises the price target from $465 to $515.
benzinga.com $1000 Invested In Waters 20 Years Ago Would Be Worth This Much Today Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.59% on an annualized basis producing an average annual return of 11.74%. Currently, Waters has a market capitalization of…
benzinga.com This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.
benzinga.com This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded SFNC, OBIO, and more.
benzinga.com This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.- benzinga.com UBS Upgrades Waters to Buy, Raises Price Target to $490 UBS analyst Doug Schenkel upgrades Waters (NYSE:WAT) from Neutral to Buy and raises the price target from $375 to $490.